Display options
Cite
Wangefjord S, Sundström M, Zendehrokh N, et al. Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. Biol Sex Differ. 2013;4(1):17doi: 10.1186/2042-6410-4-17.
Wangefjord, S., Sundström, M., Zendehrokh, N., Lindquist, K. E., Nodin, B., Jirström, K., & Eberhard, J. (2013). Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. Biology of sex differences, 4(1), 17. https://doi.org/10.1186/2042-6410-4-17
Wangefjord, Sakarias, et al. "Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study." Biology of sex differences vol. 4,1 (2013): 17. doi: https://doi.org/10.1186/2042-6410-4-17
Wangefjord S, Sundström M, Zendehrokh N, Lindquist KE, Nodin B, Jirström K, Eberhard J. Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. Biol Sex Differ. 2013 Sep 10;4(1):17. doi: 10.1186/2042-6410-4-17. PMID: 24020794; PMCID: PMC3846575.
Copy Download .nbib Format: NLM
Share it on

Biol Sex Differ. 2013 Sep 10;4(1):17. doi: 10.1186/2042-6410-4-17.

Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study.

Biology of sex differences

Sakarias Wangefjord, Magnus Sundström, Nooreldin Zendehrokh, Kajsa Ericson Lindquist, Björn Nodin, Karin Jirström, Jakob Eberhard

Affiliations

  1. Department of Clinical Sciences, Division of Pathology, Lund University, Lund, Sweden. [email protected].

PMID: 24020794 PMCID: PMC3846575 DOI: 10.1186/2042-6410-4-17

Abstract

BACKGROUND: Activating KRAS and BRAF mutations predict unresponsiveness to EGFR-targeting therapies in colorectal cancer (CRC), but their prognostic value needs further validation. In this study, we investigated the impact of KRAS codons 12 and 13, and BRAF mutations on survival from CRC, overall and stratified by sex, in a large prospective cohort study.

METHODS: KRAS codons 12 and 13, and BRAF mutations were analysed by pyrosequencing of tumours from 525 and 524 incident CRC cases in The Malmö Diet and Cancer Study. Associations with cancer-specific survival (CSS) were explored by Cox proportional hazards regression, unadjusted and adjusted for age, TNM stage, differentiation grade, vascular invasion and microsatellite instability (MSI) status.

RESULTS: KRAS and BRAF mutations were mutually exclusive. KRAS mutations were found in 191/ 525 (36.4%) cases, 82.2% of these mutations were in codon 12, 17.3% were in codon 13, and 0.5% cases had mutations in both codons. BRAF mutations were found in 78/524 (14.9%) cases. Overall, mutation in KRAS codon 13, but not codon 12, was associated with a significantly reduced CSS in unadjusted, but not in adjusted analysis, and BRAF mutation did not significantly affect survival. However, in microsatellite stable (MSS), but not in MSI tumours, an adverse prognostic impact of BRAF mutation was observed in unadjusted, but not in adjusted analysis. While KRAS mutation status was not significantly associated with sex, BRAF mutations were more common in women. BRAF mutation was not prognostic in women; but in men, BRAF mutation was associated with a significantly reduced CSS in overall adjusted analysis (HR = 3.50; 95% CI = 1.41-8.70), but not in unadjusted analysis. In men with MSS tumours, BRAF mutation was an independent factor of poor prognosis (HR = 4.91; 95% CI = 1.99-12.12). KRAS codon 13 mutation was associated with a significantly reduced CSS in women, but not in men in unadjusted, but not in adjusted analysis.

CONCLUSIONS: Results from this cohort study demonstrate sex-related differences in the prognostic value of BRAF mutations in colorectal cancer, being particularly evident in men. These findings are novel and merit further validation.

References

  1. Int J Clin Oncol. 2013 Dec;18(6):1042-8 - PubMed
  2. Acta Chir Belg. 2008 Mar-Apr;108(2):219-25 - PubMed
  3. Diagn Pathol. 2012 Aug 30;7:115 - PubMed
  4. J Clin Oncol. 2003 Jun 15;21(12):2237-46 - PubMed
  5. J Pathol. 2006 Oct;210(2):147-54 - PubMed
  6. J Intern Med. 1993 Jan;233(1):45-51 - PubMed
  7. JAMA. 2011 Apr 27;305(16):1685-94 - PubMed
  8. Int J Cancer. 2012 Sep 1;131(5):1169-78 - PubMed
  9. Mol Cancer. 2006 Jan 10;5:2 - PubMed
  10. J Clin Oncol. 2011 Apr 1;29(10):1261-70 - PubMed
  11. Int J Cancer. 2010 Dec 1;127(11):2569-75 - PubMed
  12. Biol Sex Differ. 2011 Sep 03;2:10 - PubMed
  13. Int J Mol Sci. 2012 Sep 25;13(10):12153-68 - PubMed
  14. Dis Colon Rectum. 2012 Feb;55(2):128-33 - PubMed
  15. Mod Pathol. 2006 Jan;19(1):59-68 - PubMed
  16. Br J Cancer. 2009 Aug 4;101(3):465-72 - PubMed
  17. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD005390 - PubMed
  18. Mod Pathol. 2007 Jan;20(1):15-22 - PubMed
  19. J Clin Oncol. 2008 Dec 10;26(35):5705-12 - PubMed
  20. Br J Cancer. 2011 Aug 23;105(5):666-72 - PubMed
  21. Diagn Pathol. 2013 Jan 21;8:10 - PubMed
  22. Cancer Res. 2005 Jul 15;65(14):6063-9 - PubMed
  23. JAMA. 2003 Oct 22;290(16):2149-58 - PubMed
  24. Lancet Oncol. 2010 Aug;11(8):753-62 - PubMed
  25. N Engl J Med. 2008 Oct 23;359(17):1757-65 - PubMed
  26. Gut. 2009 Jan;58(1):90-6 - PubMed
  27. Br J Cancer. 2013 Apr 30;108(8):1757-64 - PubMed
  28. Adv Enzyme Regul. 2006;46:249-79 - PubMed
  29. Ann Oncol. 2010 Dec;21(12):2396-2402 - PubMed
  30. Arch Pathol Lab Med. 2008 Jun;132(6):958-64 - PubMed
  31. Ann Surg Oncol. 2010 Feb;17(2):416-24 - PubMed
  32. PLoS One. 2012;7(10):e47483 - PubMed
  33. Cancer Res. 2003 Sep 1;63(17):5209-12 - PubMed
  34. Biol Sex Differ. 2012 Jul 02;3(1):16 - PubMed
  35. Clin Cancer Res. 2009 Jul 1;15(13):4431-8 - PubMed
  36. Lancet. 2007 Dec 15;370(9604):2020-9 - PubMed
  37. Int J Cancer. 2013 Oct 1;133(7):1624-30 - PubMed
  38. Clin Cancer Res. 2012 Feb 1;18(3):890-900 - PubMed
  39. J Clin Oncol. 2009 Apr 20;27(12):2091-6 - PubMed
  40. PLoS One. 2012;7(10):e47054 - PubMed
  41. Biol Sex Differ. 2012 Oct 16;3(1):23 - PubMed
  42. Colorectal Dis. 2009 Sep;11(7):733-9 - PubMed
  43. J Clin Oncol. 2010 Jan 20;28(3):466-74 - PubMed
  44. Ann Oncol. 2002 Sep;13(9):1438-46 - PubMed
  45. Nature. 2002 Aug 29;418(6901):934 - PubMed
  46. Br J Cancer. 2012 Feb 28;106(5):931-8 - PubMed
  47. Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7 - PubMed
  48. Ann Oncol. 2008 Mar;19(3):508-15 - PubMed
  49. Neoplasia. 2007 Jul;9(7):569-77 - PubMed
  50. J Clin Oncol. 2009 Dec 10;27(35):5931-7 - PubMed

Publication Types